Review





Similar Products

anti mouse cd45 2 fitc  (Miltenyi Biotec)
94
Miltenyi Biotec anti mouse cd45 2 fitc
LV-FXN gene therapy does not affect the engraftment and lineage commitment of HSPCs and deposits FXN protein in FRDA-relevant tissues (A) Overview of the transplantation experiment. Lineage-negative cells isolated from LY5.1 mice were transduced with LV-FXN at a multiplicity of infection (MOI) of 20 and transplanted into lethally irradiated LY5.2 recipient mice. Three months after transplantation, hematopoietic organs were analyzed by FACS, and frataxin protein levels were measured in the spleen, brain, heart, muscle, liver, and kidney by mass spectrometry. (B–D) Percentage of CD45.1 (donor-derived) <t>and</t> <t>CD45.2</t> (recipient-derived) cells in peripheral blood, bone marrow (BM), and spleen of mice transplanted with mock-untransduced ( n = 3) or LV-FXN-transduced cells ( n = 4) (upper), along with the lineage composition within the CD45.1 and CD45.2 compartments (lower). (E) Levels of human mature frataxin (ng per mg of total protein; mean ± SD) in the spleen of mice transplanted with mock-untransduced cells (mouse #304) or LV-FXN-transduced cells (mice #306, #307, and #310). (F) Total frataxin levels (ng per mg of total protein; mean ± SD) in the indicated organs of mice transplanted with mock-transduced cells (mouse #304) or LV-FXN- transduced cells with >1 vector copy number (VCN) (mice #307 and #310). ND = not determined.
Anti Mouse Cd45 2 Fitc, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+mouse+cd45+2/CD45%2E2+Antibody%2C+anti-mouse/pmc13293935-6-0-4
Average 94 stars, based on 1 article reviews
anti mouse cd45 2 fitc - by Bioz Stars, 2026-09
94/100 stars
  Buy from Supplier
cd45 2 mhcii knockout mhcii ko mice  (Miltenyi Biotec)
94
Miltenyi Biotec cd45 2 mhcii knockout mhcii ko mice
LV-FXN gene therapy does not affect the engraftment and lineage commitment of HSPCs and deposits FXN protein in FRDA-relevant tissues (A) Overview of the transplantation experiment. Lineage-negative cells isolated from LY5.1 mice were transduced with LV-FXN at a multiplicity of infection (MOI) of 20 and transplanted into lethally irradiated LY5.2 recipient mice. Three months after transplantation, hematopoietic organs were analyzed by FACS, and frataxin protein levels were measured in the spleen, brain, heart, muscle, liver, and kidney by mass spectrometry. (B–D) Percentage of CD45.1 (donor-derived) <t>and</t> <t>CD45.2</t> (recipient-derived) cells in peripheral blood, bone marrow (BM), and spleen of mice transplanted with mock-untransduced ( n = 3) or LV-FXN-transduced cells ( n = 4) (upper), along with the lineage composition within the CD45.1 and CD45.2 compartments (lower). (E) Levels of human mature frataxin (ng per mg of total protein; mean ± SD) in the spleen of mice transplanted with mock-untransduced cells (mouse #304) or LV-FXN-transduced cells (mice #306, #307, and #310). (F) Total frataxin levels (ng per mg of total protein; mean ± SD) in the indicated organs of mice transplanted with mock-transduced cells (mouse #304) or LV-FXN- transduced cells with >1 vector copy number (VCN) (mice #307 and #310). ND = not determined.
Cd45 2 Mhcii Knockout Mhcii Ko Mice, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+mouse+cd45+2/RT1B+Antibody%2C+anti-mouse%2Frat%2C+REAfinity/pm42001515-35-13-24
Average 94 stars, based on 1 article reviews
cd45 2 mhcii knockout mhcii ko mice - by Bioz Stars, 2026-09
94/100 stars
  Buy from Supplier
pd7 26 2 b11  (OriGene)
94
OriGene pd7 26 2 b11
LV-FXN gene therapy does not affect the engraftment and lineage commitment of HSPCs and deposits FXN protein in FRDA-relevant tissues (A) Overview of the transplantation experiment. Lineage-negative cells isolated from LY5.1 mice were transduced with LV-FXN at a multiplicity of infection (MOI) of 20 and transplanted into lethally irradiated LY5.2 recipient mice. Three months after transplantation, hematopoietic organs were analyzed by FACS, and frataxin protein levels were measured in the spleen, brain, heart, muscle, liver, and kidney by mass spectrometry. (B–D) Percentage of CD45.1 (donor-derived) <t>and</t> <t>CD45.2</t> (recipient-derived) cells in peripheral blood, bone marrow (BM), and spleen of mice transplanted with mock-untransduced ( n = 3) or LV-FXN-transduced cells ( n = 4) (upper), along with the lineage composition within the CD45.1 and CD45.2 compartments (lower). (E) Levels of human mature frataxin (ng per mg of total protein; mean ± SD) in the spleen of mice transplanted with mock-untransduced cells (mouse #304) or LV-FXN-transduced cells (mice #306, #307, and #310). (F) Total frataxin levels (ng per mg of total protein; mean ± SD) in the indicated organs of mice transplanted with mock-transduced cells (mouse #304) or LV-FXN- transduced cells with >1 vector copy number (VCN) (mice #307 and #310). ND = not determined.
Pd7 26 2 B11, supplied by OriGene, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+mouse+cd45+2/CD45+(PTPRC)+Mouse+Monoclonal+Antibody/pmc13049670-2-5-7
Average 94 stars, based on 1 article reviews
pd7 26 2 b11 - by Bioz Stars, 2026-09
94/100 stars
  Buy from Supplier
anti cd45 2  (Miltenyi Biotec)
94
Miltenyi Biotec anti cd45 2
LV-FXN gene therapy does not affect the engraftment and lineage commitment of HSPCs and deposits FXN protein in FRDA-relevant tissues (A) Overview of the transplantation experiment. Lineage-negative cells isolated from LY5.1 mice were transduced with LV-FXN at a multiplicity of infection (MOI) of 20 and transplanted into lethally irradiated LY5.2 recipient mice. Three months after transplantation, hematopoietic organs were analyzed by FACS, and frataxin protein levels were measured in the spleen, brain, heart, muscle, liver, and kidney by mass spectrometry. (B–D) Percentage of CD45.1 (donor-derived) <t>and</t> <t>CD45.2</t> (recipient-derived) cells in peripheral blood, bone marrow (BM), and spleen of mice transplanted with mock-untransduced ( n = 3) or LV-FXN-transduced cells ( n = 4) (upper), along with the lineage composition within the CD45.1 and CD45.2 compartments (lower). (E) Levels of human mature frataxin (ng per mg of total protein; mean ± SD) in the spleen of mice transplanted with mock-untransduced cells (mouse #304) or LV-FXN-transduced cells (mice #306, #307, and #310). (F) Total frataxin levels (ng per mg of total protein; mean ± SD) in the indicated organs of mice transplanted with mock-transduced cells (mouse #304) or LV-FXN- transduced cells with >1 vector copy number (VCN) (mice #307 and #310). ND = not determined.
Anti Cd45 2, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+mouse+cd45+2/CD45%2E2+Antibody%2C+anti-mouse/pmc13097527-135-27-28
Average 94 stars, based on 1 article reviews
anti cd45 2 - by Bioz Stars, 2026-09
94/100 stars
  Buy from Supplier
pe cy7  (Elabscience Biotechnology)
94
Elabscience Biotechnology pe cy7
LV-FXN gene therapy does not affect the engraftment and lineage commitment of HSPCs and deposits FXN protein in FRDA-relevant tissues (A) Overview of the transplantation experiment. Lineage-negative cells isolated from LY5.1 mice were transduced with LV-FXN at a multiplicity of infection (MOI) of 20 and transplanted into lethally irradiated LY5.2 recipient mice. Three months after transplantation, hematopoietic organs were analyzed by FACS, and frataxin protein levels were measured in the spleen, brain, heart, muscle, liver, and kidney by mass spectrometry. (B–D) Percentage of CD45.1 (donor-derived) <t>and</t> <t>CD45.2</t> (recipient-derived) cells in peripheral blood, bone marrow (BM), and spleen of mice transplanted with mock-untransduced ( n = 3) or LV-FXN-transduced cells ( n = 4) (upper), along with the lineage composition within the CD45.1 and CD45.2 compartments (lower). (E) Levels of human mature frataxin (ng per mg of total protein; mean ± SD) in the spleen of mice transplanted with mock-untransduced cells (mouse #304) or LV-FXN-transduced cells (mice #306, #307, and #310). (F) Total frataxin levels (ng per mg of total protein; mean ± SD) in the indicated organs of mice transplanted with mock-transduced cells (mouse #304) or LV-FXN- transduced cells with >1 vector copy number (VCN) (mice #307 and #310). ND = not determined.
Pe Cy7, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+mouse+cd45+2/PE%2FCyanine7+Anti-Mouse+CD45%2E2+Antibody/pmc13029571-269-27-28
Average 94 stars, based on 1 article reviews
pe cy7 - by Bioz Stars, 2026-09
94/100 stars
  Buy from Supplier
anti cd45 2 antibodies  (Elabscience Biotechnology)
94
Elabscience Biotechnology anti cd45 2 antibodies
LV-FXN gene therapy does not affect the engraftment and lineage commitment of HSPCs and deposits FXN protein in FRDA-relevant tissues (A) Overview of the transplantation experiment. Lineage-negative cells isolated from LY5.1 mice were transduced with LV-FXN at a multiplicity of infection (MOI) of 20 and transplanted into lethally irradiated LY5.2 recipient mice. Three months after transplantation, hematopoietic organs were analyzed by FACS, and frataxin protein levels were measured in the spleen, brain, heart, muscle, liver, and kidney by mass spectrometry. (B–D) Percentage of CD45.1 (donor-derived) <t>and</t> <t>CD45.2</t> (recipient-derived) cells in peripheral blood, bone marrow (BM), and spleen of mice transplanted with mock-untransduced ( n = 3) or LV-FXN-transduced cells ( n = 4) (upper), along with the lineage composition within the CD45.1 and CD45.2 compartments (lower). (E) Levels of human mature frataxin (ng per mg of total protein; mean ± SD) in the spleen of mice transplanted with mock-untransduced cells (mouse #304) or LV-FXN-transduced cells (mice #306, #307, and #310). (F) Total frataxin levels (ng per mg of total protein; mean ± SD) in the indicated organs of mice transplanted with mock-transduced cells (mouse #304) or LV-FXN- transduced cells with >1 vector copy number (VCN) (mice #307 and #310). ND = not determined.
Anti Cd45 2 Antibodies, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+mouse+cd45+2/PE+Anti-Mouse+CD45%2E2+Antibody/pmc13029571-270-28-30
Average 94 stars, based on 1 article reviews
anti cd45 2 antibodies - by Bioz Stars, 2026-09
94/100 stars
  Buy from Supplier

Image Search Results


LV-FXN gene therapy does not affect the engraftment and lineage commitment of HSPCs and deposits FXN protein in FRDA-relevant tissues (A) Overview of the transplantation experiment. Lineage-negative cells isolated from LY5.1 mice were transduced with LV-FXN at a multiplicity of infection (MOI) of 20 and transplanted into lethally irradiated LY5.2 recipient mice. Three months after transplantation, hematopoietic organs were analyzed by FACS, and frataxin protein levels were measured in the spleen, brain, heart, muscle, liver, and kidney by mass spectrometry. (B–D) Percentage of CD45.1 (donor-derived) and CD45.2 (recipient-derived) cells in peripheral blood, bone marrow (BM), and spleen of mice transplanted with mock-untransduced ( n = 3) or LV-FXN-transduced cells ( n = 4) (upper), along with the lineage composition within the CD45.1 and CD45.2 compartments (lower). (E) Levels of human mature frataxin (ng per mg of total protein; mean ± SD) in the spleen of mice transplanted with mock-untransduced cells (mouse #304) or LV-FXN-transduced cells (mice #306, #307, and #310). (F) Total frataxin levels (ng per mg of total protein; mean ± SD) in the indicated organs of mice transplanted with mock-transduced cells (mouse #304) or LV-FXN- transduced cells with >1 vector copy number (VCN) (mice #307 and #310). ND = not determined.

Journal: Cell Reports Medicine

Article Title: Therapeutic activity of a hematopoietic stem cell-delivered cell-penetrating frataxin in Friedreich’s ataxia models

doi: 10.1016/j.xcrm.2026.102803

Figure Lengend Snippet: LV-FXN gene therapy does not affect the engraftment and lineage commitment of HSPCs and deposits FXN protein in FRDA-relevant tissues (A) Overview of the transplantation experiment. Lineage-negative cells isolated from LY5.1 mice were transduced with LV-FXN at a multiplicity of infection (MOI) of 20 and transplanted into lethally irradiated LY5.2 recipient mice. Three months after transplantation, hematopoietic organs were analyzed by FACS, and frataxin protein levels were measured in the spleen, brain, heart, muscle, liver, and kidney by mass spectrometry. (B–D) Percentage of CD45.1 (donor-derived) and CD45.2 (recipient-derived) cells in peripheral blood, bone marrow (BM), and spleen of mice transplanted with mock-untransduced ( n = 3) or LV-FXN-transduced cells ( n = 4) (upper), along with the lineage composition within the CD45.1 and CD45.2 compartments (lower). (E) Levels of human mature frataxin (ng per mg of total protein; mean ± SD) in the spleen of mice transplanted with mock-untransduced cells (mouse #304) or LV-FXN-transduced cells (mice #306, #307, and #310). (F) Total frataxin levels (ng per mg of total protein; mean ± SD) in the indicated organs of mice transplanted with mock-transduced cells (mouse #304) or LV-FXN- transduced cells with >1 vector copy number (VCN) (mice #307 and #310). ND = not determined.

Article Snippet: Anti-mouse CD45.2 FITC , Miltenyi , Cat# 130-102-458; RRID:AB_2660717.

Techniques: Transplantation Assay, Isolation, Transduction, Infection, Irradiation, Mass Spectrometry, Derivative Assay, Plasmid Preparation